title: The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy.
abstract: OBJECTIVE
  Cutaneous T-cell lymphomas represent clinically and biologically a heterogeneous group of non-Hodgkin lymphomas according to the new revised European Organization for Research and Treatment of Cancer and World Health Organization consensus classification for cutaneous lymphomas. Recent progress in immune and molecular biology and novel therapeutic targets have increased our understanding of these diseases and have led to novel treatment approaches. This review outlines the most recent advances.
  
  
  RESULTS
  New immunologic and molecular findings may influence tumor phenotype and growth and provide a biologic basis for novel treatment approaches. Several reports have focused on new prognostic markers. Among the novel therapies for cutaneous T-cell lymphoma, interleukin-2 fusion toxins, monoclonal antibodies, histone deacetylase inhibitors, and immunomodulatory cytosine-phosphorothiolated guanine oligomers have shown promising results and are under further investigation.
  
  
  CONCLUSIONS
  This review provides an update of recent findings of immunologic, molecular, and cytogenetic features and treatment approaches for patients with cutaneous T-cell lymphoma with special emphasis on mycosis fungoides and Sezary syndrome.
authors.affiliation: Department of Dermatology, Division of Hematology/Oncology, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA.
authors.forename: Christiane
authors.initials: C
authors.lastname: Querfeld
authors.forename: Steven T
authors.initials: ST
authors.lastname: Rosen
authors.forename: Joan
authors.initials: J
authors.lastname: Guitart
authors.forename: Timothy M
authors.initials: TM
authors.lastname: Kuzel
mesh_terms: D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000473:pathology* / Q000628:therapy*; D009182:Mycosis Fungoides / Q000188:drug therapy / Q000473:pathology; D012751:Sezary Syndrome / Q000188:drug therapy / Q000473:pathology; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy
chemical_list: D016588:Anticarcinogenic Agents